Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 and CFZ533 in systemic lupus erythematosus: randomized placebo-controlled phase 2 trial
jRCT2080224123Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ianalumab and iscalimab in systemic lupus erythematosus (SLE) (4 arms), sponsored by Novartis. Primary endpoints: Primary pharmacodynamic and clinical efficacy endpoint for VAY736 (Cohort 1) and Primary pharmacodynamic and clinical efficacy endpoint for CFZ533 (Cohort 2). Started Nov 2018; status: completed.
02
Drugs
ianalumabiscalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080224123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224123.